We are thrilled to announce the publication of our study, “Humanized anti-BAMBI monoclonal antibody as a novel therapeutic strategy for psoriatic arthritis”, in Journal of Translational Medicine! This achievement marks an important milestone for Inhibitec and represents a significant step forward in the development of our humanized anti-BAMBI monoclonal antibody (hB101.37).
Our findings demonstrate its therapeutic efficacy across different preclinical murine models of psoriasis and psoriatic arthritis (PsA). The study also confirms its innovative and disruptive mechanism of action, based on modulating the balance between pro-inflammatory Th17 cells and regulatory T cells (Tregs). Furthermore, comparative studies against currently available anti-IL-17A treatments and comprehensive toxicological assessments support the antibody’s therapeutic potential and preclinical safety profile.
This publication marks a significant step forward in our mission to make a meaningful difference in the lives of patients with psoriasis and PsA. We remain committed to advancing better treatment options and improving psoriasis and PsA patients’ quality of life.
Read the full publication here: https://rdcu.be/tu6dAovDFmQa
We would like to thank everyone who contributed to this work.